CNSX:EHC

Stock Analysis Report

Executive Summary

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets.


Snowflake Analysis

Imperfect balance sheet and overvalued.

Share Price & News

How has Eviana Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EHC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

EHC

2.4%

CA Chemicals

0.1%

CA Market


1 Year Return

-92.2%

EHC

-23.3%

CA Chemicals

4.5%

CA Market

Return vs Industry: EHC underperformed the Canadian Chemicals industry which returned -7% over the past year.

Return vs Market: EHC underperformed the Canadian Market which returned 10.4% over the past year.


Shareholder returns

EHCIndustryMarket
7 Day0%2.4%0.1%
30 Day0%-3.9%0.9%
90 Day0%-10.6%3.7%
1 Year-92.2%-92.2%-20.6%-23.3%7.8%4.5%
3 Yearn/a-31.2%-35.4%18.2%7.5%
5 Yearn/a-26.7%-34.7%33.7%14.2%

Price Volatility Vs. Market

How volatile is Eviana Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eviana Health undervalued compared to its fair value and its price relative to the market?

0.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EHC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EHC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EHC is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: EHC is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EHC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EHC is good value based on its PB Ratio (0.3x) compared to the CA Chemicals industry average (1.3x).


Next Steps

Future Growth

How is Eviana Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.6%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eviana Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Eviana Health performed over the past 5 years?

-47.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EHC is currently unprofitable.

Growing Profit Margin: EHC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EHC is unprofitable, and losses have increased over the past 5 years at a rate of -47.1% per year.

Accelerating Growth: Unable to compare EHC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EHC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-18.6%).


Return on Equity

High ROE: EHC has a negative Return on Equity (-87.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Eviana Health's financial position?


Financial Position Analysis

Short Term Liabilities: EHC's short term assets (CA$11.1M) exceed its short term liabilities (CA$2.3M).

Long Term Liabilities: EHC's short term assets (CA$11.1M) exceed its long term liabilities (CA$8.0M).


Debt to Equity History and Analysis

Debt Level: EHC's debt to equity ratio (170%) is considered high.

Reducing Debt: Insufficient data to determine if EHC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: EHC has a high level of physical assets or inventory.

Debt Coverage by Assets: EHC's debt is covered by short term assets (assets are 1.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if EHC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EHC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Eviana Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EHC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EHC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EHC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EHC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average board tenure


CEO

Avram Adizes 0

2.5yrs

Tenure

CA$120,000

Compensation

Dr. Avram Adizes, Ph.D., P.E., serves as the Chief Technology Officer of Phoenix Capital Partners Inc. Dr. Adizes is responsible for Technology assessment and evaluation. Dr. Adizes serves as Chairman and  ...


CEO Compensation Analysis

Compensation vs Market: Avram's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD165.67K).

Compensation vs Earnings: Insufficient data to compare Avram's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Avram Adizes
Chairman of the Board & CEO2.5yrsCA$120.00k7.49% CA$116.4k
Wai Kong Au
CFO & Director6.7yrsCA$60.00k0.92% CA$14.3k
Joel Sherlock
Member of Advisory Board1.6yrsno datano data
Ljiljana Vujotic
Director2.5yrsCA$100.00k6.28% CA$97.5k

2.5yrs

Average Tenure

Experienced Board: EHC's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.


Top Shareholders

Company Information

Eviana Health Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eviana Health Corporation
  • Ticker: EHC
  • Exchange: CNSX
  • Founded: 2011
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CA$1.553m
  • Shares outstanding: 23.90m
  • Website: https://eviana.ca

Location

  • Eviana Health Corporation
  • 5728 East Boulevard
  • Vancouver
  • British Columbia
  • V6M 4M4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EHCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 2017
EVNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2017
1CPDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2017

Biography

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets. It is also involved in the growing of industrial hemp and extraction of cannabidiol. The company was formerly known as C&C Cosmeceuticals Corp. and changed its name to Eviana Health Corporation in May 2017. Eviana Health Corporation was incorporated in 2011 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/03 01:02
End of Day Share Price2019/11/05 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.